Olivier Ballo, Fagr Eladly, Stefan Büttner, Jan Alexander Stratmann, Sarah Rudolf, Uta Brunnberg, Eva-Maria Kreisel, Björn Steffen, Sebastian Alexander Wagner, Fabian Finkelmeier, Hubert Serve, Christian Hubertus Brandts
- Acute kidney injury (AKI) complicates the clinical course of hospitalized patients by increasing need for intensive care treatment and mortality. There is only little data about its impact on AML patients undergoing intensive induction chemotherapy. In this study, we analyzed the incidence as well as risk factors for AKI development and its impact on the clinical course of AML patients undergoing induction chemotherapy. We retrospectively analyzed data from 401 AML patients undergoing induction chemotherapy between 2007 and 2019. AKI was defined and stratified according to KIDGO criteria by referring to a defined baseline serum creatinine measured on day 1 of induction chemotherapy. Seventy-two of 401 (18%) AML patients suffered from AKI during induction chemotherapy. AML patients with AKI had more days with fever (7 vs. 5, p = 0.028) and were more often treated on intensive care unit (45.8% vs. 10.6%, p < 0.001). AML patients with AKI had a significantly lower complete remission rate after induction chemotherapy and, with 402 days, a significantly shorter median overall survival (OS) (median OS for AML patients without AKI not reached). In this study, we demonstrate that the KIDGO classification allows mortality risk stratification for AML patients undergoing induction chemotherapy. Relatively mild AKI episodes have impact on the clinical course of these patients and can lead to chronic impairment of kidney function. Therefore, we recommend incorporating risk factors for AKI in decision-making considering nutrition, fluid management, as well as the choice of potentially nephrotoxic medication in order to decrease the incidence of AKI.
MetadatenAuthor: | Olivier BalloORCiDGND, Fagr EladlyGND, Stefan BüttnerORCiDGND, Jan Alexander StratmannORCiDGND, Sarah RudolfGND, Uta BrunnbergGND, Eva-Maria Kreisel, Björn SteffenGND, Sebastian Alexander WagnerORCiDGND, Fabian FinkelmeierORCiDGND, Hubert ServeORCiDGND, Christian Hubertus BrandtsORCiDGND |
---|
URN: | urn:nbn:de:hebis:30:3-813130 |
---|
DOI: | https://doi.org/10.1007/s00277-021-04482-3 |
---|
ISSN: | 1432-0584 |
---|
Parent Title (English): | Annals of hematology |
---|
Publisher: | Springer |
---|
Place of publication: | Berlin ; Heidelberg ; New York |
---|
Document Type: | Article |
---|
Language: | English |
---|
Date of Publication (online): | 2021/03/11 |
---|
Date of first Publication: | 2021/03/11 |
---|
Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
---|
Release Date: | 2024/01/31 |
---|
Tag: | Acute kidney failure; Acute myeloid leukemia; Induction chemotherapy; Intensive care treatment; Survival |
---|
Volume: | 100 |
---|
Issue: | 5 |
---|
Page Number: | 9 |
---|
First Page: | 1159 |
---|
Last Page: | 1167 |
---|
Note: | Open Access funding enabled and organized by Projekt DEAL. |
---|
HeBIS-PPN: | 517755483 |
---|
Institutes: | Medizin |
---|
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Sammlungen: | Universitätspublikationen |
---|
Licence (German): | Creative Commons - CC BY - Namensnennung 4.0 International |
---|